文献速递神经肌肉病

抗接触蛋白-1自身免疫性结病长期随访研究

Long-Term Follow Up in Anti-Contactin-1 Autoimmune Nodopathy.
PubMed 文献 · Ann Neurol · 2024-11-27

研究纳入31例抗接触蛋白-1(CNTN1)阳性自身免疫性结病患者,回顾性分析临床特征与治疗反应,并在基线和随访时检测自身抗体、血清神经丝轻链(sNfL)和血清CNTN1水平。结果发现利妥昔单抗有效率高,成功治疗后临床和免疫学复发不常见,提示可能无需持续治疗;抗体和生物标志物有助于监测疾病状态。

要点

  • 31例抗CNTN1阳性自身免疫性结病患者中,97%接受静脉注射免疫球蛋白,但仅1例达到缓解。
  • 利妥昔单抗在22例中21例(95.5%)有效,多数(72%)仅接受一个疗程。
  • 有效治疗后中位随访25个月,4例(12.9%)复发。

核心结论

  • 抗CNTN1阳性自身免疫性结病患者具有特征性临床表型,成功治疗后临床和免疫学复发不常见,提示可能不需要持续治疗。
  • 抗CNTN1抗体、sNfL和sCNTN1水平可用于监测这些患者的疾病状态。

研究设计与样本

  • 回顾性纳入本实验室检测到抗CNTN1阳性的自身免疫性结病患者,共31例,收集临床特征和治疗反应,分析基线和随访时的自身抗体、sNfL和sCNTN1水平。

主要发现

  • 患者表现为进行性感觉运动神经病(76.7%),近端(74.2%)和远端(87.1%)受累,共济失调(71.4%),严重残疾(最低点INCAT中位数8)。
  • 11例(35%)有肾脏受累;97%接受静脉注射免疫球蛋白,仅1例达到缓解;22例(71%)接受糖皮质激素,其中3例(14%)无需进一步治疗。
  • 利妥昔单抗在22例中21例(95.5%)有效,多数(72%)接受一个疗程;有效治疗后中位随访25个月(范围12-48个月),4例(12.9%)复发。
  • 抗CNTN1滴度与采样时临床量表相关,治疗后所有患者转阴,但1例例外(20/21)。
  • 抗CNTN1阳性患者sNfL水平显著高于健康对照(135.9 pg/ml vs 7.48 pg/ml),sCNTN1显著低于健康对照(25.03 pg/ml vs 22,186 pg/ml),p < 0.0001;成功治疗后两者均恢复正常。

关键数值与推荐

  • 抗CNTN1阳性患者sNfL水平显著高于健康对照(135.9 pg/ml vs 7.48 pg/ml,p < 0.0001)。
  • 抗CNTN1阳性患者sCNTN1水平显著低于健康对照(25.03 pg/ml vs 22,186 pg/ml,p < 0.0001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To analyze long-term clinical and biomarker features of anti-contactin-1 (CNTN1) autoimmune nodopathy (AN). METHODS: Patients with anti-CNTN1+ autoimmune nodopathy detected in our laboratory from which clinical information was available were included. Clinical features and treatment response were retrospectively collected. Autoantibody, serum neurofilament light chain (sNfL), and serum CNTN1 levels (sCNTN1) were analyzed at baseline and follow up. RESULTS: A total of 31 patients were included. Patients presented with progressive sensory motor neuropathy (76.7%) with proximal (74.2%) and distal involvement (87.1%), ataxia (71.4%), and severe disability (median INCAT at nadir of 8). A total of 11 patients (35%) showed kidney involvement. Most patients (97%) received intravenous immunoglobulin, but only 1 achieved remission with intravenous immunoglobulin. A total of 22 patients (71%) received corticosteroids, and 3 of them (14%) did not need further treatments. Rituximab was effective in 21 of 22 patients (95.5%), with most of them (72%) receiving a single course. Four patients (12.9%) relapsed after a median follow up of 25 months after effective treatment (12-48 months). Anti-CNTN1 titers correlated with clinical scales at sampling and were negative after treatment in all patients, but 1 (20/21). sNfL levels were significantly higher and sCNTN1 significantly lower in anti-CNTN1+ patients than in healthy controls (sNfL: 135.9 pg/ml vs 7.48 pg/ml, sCNTN1: 25.03 pg/ml vs 22,186 pg/ml, p < 0.0001). Both sNfL and sCNTN1 returned to normal levels after successful treatment. INTERPRETATION: Patients with anti-CNTN1+ autoimmune nodopathy have a characteristic clinical profile. Clinical and immunological relapses are infrequent after successful treatment, suggesting that continuous treatment is unnecessary. Anti-CNTN1 antibodies, sNfL, and sCNTN1 levels are useful to monitor disease status in these patients. ANN NEUROL 2025;97:529-541.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Caballero-Ávila M, Martín-Aguilar L, Pascual-Goñi E, et al. Long-Term Follow Up in Anti-Contactin-1 Autoimmune Nodopathy. Ann Neurol. 2024. PMID: 39601182. doi:10.1002/ana.27142

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。